<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39435167</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1846-7482</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Biochemia medica</Title><ISOAbbreviation>Biochem Med (Zagreb)</ISOAbbreviation></Journal><ArticleTitle>CCL20 chemokine and other proinflammatory markers after Ad26.COV2.S vaccination.</ArticleTitle><Pagination><StartPage>030706</StartPage><MedlinePgn>030706</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">030706</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.11613/BM.2024.030706</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">In highly stressed circumstances, such as COVID-19 pandemic, biomarkers of the vaccine-induced immunity could be especially convenient. The main aim of our study was to determine C-C motif ligand 20 (CCL20) concentration after Ad26.COV2.S vaccination in regard to more common proinflammatory molecules and its correlation with anti-SARS-CoV-2 antibody concentration. Secondly, we investigated inflammatory and immunologic profile differences between patients with and without arterial hypertension.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">The study included 84 subjects vaccinated with Ad26.COV2.S vaccine. Concentration of CCL20, interleukin (IL) 6, C-reactive protein (CRP) was investigated before, 7 and 14 days after vaccination and concentration of anti-SARS-CoV-2 IgG antibody 7 and 14 days after vaccination. All the markers were measured by well-established laboratory methods.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">There were no statistically significant changes of CCL20 and IL-6 concentration after the vaccination. The obtained results have shown statistically significant differences for CRP (P = 0.006) concentrations between 3 time points and SARS-CoV-2 IgG antibody (P &lt; 0.001) concentrations between 2 time points. CCL20 did not correlate with IL-6, CRP or anti-SARS-CoV-2 IgG antibody concentration. Statistically significant difference for CRP (P = 0.025) concentration between 3 time points was observed in the subgroup of subjects with arterial hypertension.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Although our results did not show changes in CCL20 concentration after the vaccination, possibly due to the study timeframe, further investigations on chemokine profile post SARS-CoV-2 immunization could facilitate the recognition of specific patterns of response (supra- or sub-optimal) to the vaccine.</AbstractText><CopyrightInformation>Croatian Society of Medical Biochemistry and Laboratory Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ivanko</LastName><ForeName>Iva</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Haematology, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanžek</LastName><ForeName>Milena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ćelap</LastName><ForeName>Ivana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margetić</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Catholic University of Croatia, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marijančević</LastName><ForeName>Domagoj</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Catholic University of Croatia, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Josipović</LastName><ForeName>Josipa</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Medicine, Catholic University of Croatia, Zagreb, Croatia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nephrology, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaćina</LastName><ForeName>Petar</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Haematology, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Dental Medicine, University of Zagreb, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Croatia</Country><MedlineTA>Biochem Med (Zagreb)</MedlineTA><NlmUniqueID>9610305</NlmUniqueID><ISSNLinking>1330-0962</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054418">Chemokine CCL20</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C108355">CCL20 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054418" MajorTopicYN="Y">Chemokine CCL20</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="Y">C-Reactive Protein</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="Y">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chemokine</Keyword><Keyword MajorTopicYN="N">immunity</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>Potential conflict of interest None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>10</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>10</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39435167</ArticleId><ArticleId IdType="pmc">PMC11493461</ArticleId><ArticleId IdType="doi">10.11613/BM.2024.030706</ArticleId><ArticleId IdType="pii">bm-34-3-030706</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zemans RL, Colgan SP, Downey GP. Transepithelial migration of neutrophils: Mechanisms and implications for acute lung injury. Am J Respir Cell Mol Biol. 2009;40:519–35. 10.1165/rcmb.2008-0348TR</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2008-0348TR</ArticleId><ArticleId IdType="pmc">PMC2677434</ArticleId><ArticleId IdType="pubmed">18978300</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med. 2008;205:3119–31. 10.1084/jem.20082292</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20082292</ArticleId><ArticleId IdType="pmc">PMC2605227</ArticleId><ArticleId IdType="pubmed">19047440</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen-Nissen E, Fiore-Gartland A, Ballweber Fleming L, Carpp LN, Naidoo AF, Harper MS, et al. Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. PLoS Pathog. 2021;17:e1009363. 10.1371/journal.ppat.1009363</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009363</ArticleId><ArticleId IdType="pmc">PMC7959397</ArticleId><ArticleId IdType="pubmed">33720973</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschi C, Terpos E, Rosati M, Angel M, Bear J, Stellas D, et al. Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021;36:109504. 10.1016/j.celrep.2021.109504</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109504</ArticleId><ArticleId IdType="pmc">PMC8299183</ArticleId><ArticleId IdType="pubmed">34352226</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar NP, Banurekha VV, CP GK, Nancy A, Padmapriyadarsini C, Mary AS, et al. . Prime-boost vaccination with Covaxin/BBV152 induces heightened systemic cytokine and chemokine responses. Front Immunol. 2021;12:752397. 10.3389/fimmu.2021.752397</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.752397</ArticleId><ArticleId IdType="pmc">PMC8554328</ArticleId><ArticleId IdType="pubmed">34721425</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HK, Go J, Sung H, Kim SW, Walter M, Knabl L, et al. Heterologous ChAdOx1-BNT162b2 vaccination in Korean cohort induces robust immune and antibody responses that includes Omicron. iScience. 2022;25:104473. 10.1016/j.isci.2022.104473</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.104473</ArticleId><ArticleId IdType="pmc">PMC9132682</ArticleId><ArticleId IdType="pubmed">35637788</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurlevik SL, Ozsurekci Y, Sağ E, Derin Oygar P, Kesici S, Akca ÜK, et al. Cuceoglu. The difference of the inflammatory milieu in MIS-C and severe COVID-19. Pediatr Res. 2022;92:1805–14. 10.1038/s41390-022-02029-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41390-022-02029-4</ArticleId><ArticleId IdType="pmc">PMC8963396</ArticleId><ArticleId IdType="pubmed">35352005</ArticleId></ArticleIdList></Reference><Reference><Citation>Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003;14:409–26. 10.1016/S1359-6101(03)00049-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1359-6101(03)00049-2</ArticleId><ArticleId IdType="pubmed">12948524</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamauchi K, Akbar SM, Horiike N, Michitaka K, Onji M. Increased serum levels of macrophage inflammatory protein-3α in chronic viral hepatitis: prognostic importance of macrophage inflammatory protein-3α during interferon therapy in chronic hepatitis C. J Viral Hepat. 2002;9:213–20. 10.1046/j.1365-2893.2002.00354.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2893.2002.00354.x</ArticleId><ArticleId IdType="pubmed">12010510</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdecchia P, Coiro S, Notaristefano F, Santucci A, De Angelis F, D’Ammando M, et al. Cardiac complications of COVID-19 vaccination: now we know more. Eur Heart J Suppl. 2022;24:I190–6. 10.1093/eurheartjsupp/suac093</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartjsupp/suac093</ArticleId><ArticleId IdType="pmc">PMC9653149</ArticleId><ArticleId IdType="pubmed">36380799</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanko I, Ćelap I, Margetić S, Marijančević D, Josipović J, Gaćina P. Changes in haemostasis and inflammatory markers after mRNA BNT162b2 and vector Ad26.CoV2.S SARS-CoV-2 vaccination. Thromb Res. 2023;228:137–44. 10.1016/j.thromres.2023.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2023.06.008</ArticleId><ArticleId IdType="pmc">PMC10264328</ArticleId><ArticleId IdType="pubmed">37329722</ArticleId></ArticleIdList></Reference><Reference><Citation>Brambilla M, Canzano P, Valle PD, Becchetti A, Conti M, Alberti M, et al. Head-to-head comparison of four COVID-19 vaccines on platelet activation, coagulation and inflammation. The TREASURE study. Thromb Res. 2023;223:24–33. 10.1016/j.thromres.2023.01.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2023.01.015</ArticleId><ArticleId IdType="pmc">PMC9846886</ArticleId><ArticleId IdType="pubmed">36702064</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. ENSEMBLE Study Group . Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384:2187–201. 10.1056/NEJMoa2101544</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM. i sur. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021;384:1824–35. 10.1056/NEJMoa2034201</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034201</ArticleId><ArticleId IdType="pmc">PMC7821985</ArticleId><ArticleId IdType="pubmed">33440088</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowski SR, Søgaard OS, Tolstrup M, Stærke NB, Lundgren J, Østergaard L, et al. Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis. Front Immunol. 2021;12:779453. 10.3389/fimmu.2021.779453</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.779453</ArticleId><ArticleId IdType="pmc">PMC8649717</ArticleId><ArticleId IdType="pubmed">34887867</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher A, Selleng K, Palankar R, Wesche J, Handtke S, Wolff M. i sur. Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood. 2021;138:2256–68. 10.1182/blood.2021013231</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021013231</ArticleId><ArticleId IdType="pmc">PMC8483989</ArticleId><ArticleId IdType="pubmed">34587242</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19. N Engl J Med. 2021;384:2187–201. 10.1056/NEJMoa2101544</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>